**Табела. 9.8** Компетентност ментора

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Име и презиме** | | | [Момир Миков](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Mikov%20Momir%20M&samoar&.WW3SJ7axWUn) | | | | | | | | | |
| **Звање** | | | Редовни професор | | | | | | | | | |
| **Ужа научна, уметничка односно стручна област** | | | Фармакологија, токсикологија и клиничка фармакологија | | | | | | | | | |
| **Академска каријера** | | Година | Институција | | | | Ужа научна, уметничка односно стручна област | | | | | |
| Избор у звање | | 1999. | Медицински факултет,Универзитет у Новом Саду | | | | Фармакологија и токсикологија | | | | | |
| Докторат | | 1986. | Медицински факултет, , Универзитет у Новом Саду | | | | Фармакологија и токсикологија | | | | | |
| Специјализација | | 1988. | Медицински факултет, , Универзитет у Новом Саду | | | | Клиничка фармакологија | | | | | |
| Магистратура | | 1983. | Медицински факултет, , Универзитет у Новом Саду | | | | Фармакологија и токсикологија | | | | | |
| Диплома | | 1980. | Медицински факултет, , Универзитет у Новом Саду | | | | Фармакологија и токсикологија | | | | | |
| **Списак дисертација-докторских уметничких пројеката а у којима је наставнк ментор или је био ментор у претходних 10 година** | | | | | | | | | | | | |
| Р.Б. | Наслов дисертације- докторског уметничког пројекта | | | | Име кандидата | | | | \*пријављена | | \*\* одбрањена | |
| 1. | ОДРЕЂИВАЊЕ КОНЦЕНТРАЦИЈЕ МЕТАБОЛИТА АЗАТИОПРИНА У ЦИЉУ ОПТИМИЗАЦИЈЕ ЛЕЧЕЊА ИНФЛАМАТОРНИХ БОЛЕСТИ ЦРЕВА | | | | Олгица Латиновић Бошњак | | | | 2019. | |  | |
| 2. | УТИЦАЈ ТЕРАПИЈЕ ИНХИБИТОРА ФАКТОРА ТУМОРСКЕ НЕКРОЗЕ НА МИНЕРАЛНУ КОШТАНУ ГУСТИНУ И КОШТАНЕ БИОХЕМИЈСКЕ МАРКЕРЕ-ПРОКОЛАГЕН ТИП 1 Н-ТЕРМИНАЛНИ ПРОПЕПТИД И БЕТА-КРОСЛАПС КОД БОЛЕСНИЦА СА РЕУМАТОИДНИМ АРТРИТИСОМ | | | | Тања Јанковић | | | |  | | 2020. | |
| 3. | УТИЦАЈ ЖУЧНИХ КИСЕЛИНА НА ПРОДОР У ЋЕЛИЈЕ И ТКИВА И ФАРМАКОДИНАМИКУ ДОКСОРУБИЦИНА | | | | Бојан Станимиров | | | |  | | 2018. | |
| 4. | УТИЦАЈ СОЛИ ЖУЧНИХ КИСЕЛИНА НА ПРОДОР И МЕТАБОЛИЗАМ СИМВАСТАТИНА У ПРОБИОТСКИМ БАКТЕРИЈАМА | | | | Маја Ђанић | | | |  | | 2016. | |
| 5. | УТИЦАЈ СИНТЕТСКЕ И ПРИРОДНЕ ЖУЧНЕ КИСЕЛИНЕ НА ОКСИДАТИВНИ СТРЕС И АПОПТОЗУ ХЕПАТОЦИТА | | | | Бојана Андрејић Вишњић | | | |  | | 2016. | |
| 6. | ТРАНСФЕР КРОЗ ФЕТОПЛАЦЕНТАРНУ МЕМБРАНУ И ФАРМАКОКИНЕТИКА ЛЕКОВА У ПРЕМЕДИКАЦИЈИ КОД ЕЛЕКТИВНИХ ЦАРСКИХ РЕЗОВА | | | | Јована Паунковић | | | |  | | 2014. | |
| 7. | ИСПИТИВАЊЕ СОЛИ ЖУЧНИХ КИСЕЛИНА КАО ЕКСЦИПИЈЕНАСА У ТАБЛЕТАМА РАНИТИДИНА, АМИНОФИЛИНА И ФЕНОБАРБИТОНА | | | | Марта Почуча | | | |  | | 2013. | |
| \*Година у којој је дисертација-докторски уметнички пројекат пријављена-пријављен (само за дисертације-докторске уметничке пројекте које су у току), \*\* Година у којој је дисертација-докторски уметнички пројекат одбрањена (само за дисертације-докторско уметничке пројекте из ранијег периода) | | | | | | | | | | | | |
| **Категоризација публикације научних радова из области датог студијског програма према класификацији ресорног Министарства просвете, науке и технолошког развоја а у складу са допунским захтевевима стандарда за дато поље (м** | | | | | | | | | | | | |
| Р.б. | Публикација | | | | | | | ISI | | M | | IF |
| 1. | Miljkovic M, Rancic N, Kovacevic A, Cikota-Aleksic B, Skadric I, Jecevic V, Mikov Momir, Dragojevic-Simic V. [Influence of Gender, Body Mass Index, and Age on the Pharmacokinetics of Itraconazole in Healthy Subjects: Non-Compartmental Versus Compartmental Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240599/pdf/fphar-13-796336.pdf). Front Pharmacol. 2022;13:796336. [doi.org/](https://doi.org/10.3390/biomedicines10010111)[[10.3389/fphar.2022.796336](https://doi.org/10.3390/biomedicines10010111)](https://doi.org/10.3389/fphar.2022.879170) | | | | | | | 50/279  (2021) | | 21 (2021) | | 5.988  (2021) |
| 2. | Mooranian A, Chester J, Johnston E, Ionescu CM, Walker D, Jones M, Wagle SR, Kovačević B, Foster T, **Mikov Momir**, Al-Salami H. [Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313251/pdf/biomolecules-12-00877.pdf). Biomolecules. 2022;12(7):877. [doi.org/10.3390/biom12070877](https://doi.org/10.3390/nano12040647) | | | | | | | 75/296  (2021) | | 21 (2021) | | 6.064  (2021) |
| 3. | Milijašević B, Steinbach M, **Mikov Momir**, Rašković A, Čapo I, Živković J, Borišev I, Čanji-Panić J, Teofilović B, Vujćić M, Popović M. [Impact of winter savory extract (Satureja montana L.) on biochemical parameters in serum and oxidative status of liver with application of the principal component analysis in extraction solvent selection](https://www.europeanreview.org/wp/wp-content/uploads/4721-4734.pdf). Eur Rev Med Pharmacol Sci. 2022;26(13):4721-34. [[doi.org/10.26355/eurrev\_202207\_29197](https://doi.org/10.3390/gels8010035)](https://doi.org/10.2174/1871520621666210608102452) | | | | | | | 125/279  (2021) | | 22 (2021) | | 3.784  (2021) |
| 4. | Lazarević S, Đanić M, Al-Salami H, Mooranian A, Mikov M. [Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease](https://www.frontiersin.org/articles/10.3389/fphar.2022.879170/full). Front Pharmacol. 2022;13:879170. [doi.org/[10.3389/fphar.2022.879170](https://doi.org/10.3389/fphar.2022.879170)](https://doi.org/10.3390/biomedicines10010111) | | | | | | | 50/279  (2021) | | 21 (2021) | | 5.988  (2021) |
| 5. | Kovačević B, Jones M, Ionescu CM, Walker D, Wagle SR, Chester J, Foster T, Johnston E, Brown D, **Mikov M**, Mooranian A, Al-Salami H. [The emerging role of bile acids as critical components in nanotechnology and bioegineering: pharmacology, formulation optimizers and hydrogel-biomaterial applications](https://www.sciencedirect.com/science/article/pii/S0142961222000989). Biomaterials. 2022;283:121459. [doi.org/[10.1016/j.biomaterials.2022.121459](https://doi.org/10.1016/j.biomaterials.2022.121459)](https://doi.org/10.3390/ijms23020836) | | | | | | | 4/98  (2021) | | 21a (2021) | | 15.304  (2021) |
| 6. | Pavlović N, Milošević N, Đanić M, Goločorbin-Kon S, Stanimirov B, Stankov K, **Mikov M**. Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: A Pharmacoinformatic Preliminary Study. Anticancer Agents Med Chem. 2022;22(7):1407-13. [doi.org/[10.2174/1871520621666210608102452](https://doi.org/10.2174/1871520621666210608102452)](https://doi.org/10.3390/gels8010035) | | | | | | | 46/63  (2021) | | 23 (2021) | | 2.527  (2021) |
| 7. | Mooranian A, Jones M, Walker D, Ionescu CM, Wagle SR, Kovačević B, Chester J, Foster T, Johnston E, Kuthubutheen J, Brown D, Atlas MD, **Mikov M**, Al-Salami H. [Pharmacological dose-effect profiles of various concentrations of humanised primary bile acid in encapsulated cells](https://mdpi-res.com/d_attachment/nanomaterials/nanomaterials-12-00647/article_deploy/nanomaterials-12-00647.pdf?version=1644918313). Nanomaterials. 2022;12(4):647. [doi.org/10.3390/nano12040647](https://doi.org/10.3390/nano12040647) | | | | | | | 37/161  (2021) | | 21 (2021) | | 5.719  (2021) |
| 8. | Mooranian A, Ionescu CM, Wagle SR, Kovačević B, Walker D, Jones M, et al ... **Mikov M**, Al-Salami H. [Taurine grafted micro-implants improved functions without direct dependency between interleukin-6 and the bile acid lithocholic acid in plasma](https://mdpi-res.com/d_attachment/biomedicines/biomedicines-10-00111/article_deploy/biomedicines-10-00111-v2.pdf). Biomedicines. 2022;10(1):111. | | | | | | | 33/276  (2020) | | 21 (2020) | | 6.081  (2020) |
| 9. | Jones M, Ionescu CM, Walker D, Wagle SR, Kovačević B, Chester J, et al ... **Mikov M**, ... Al-Salami H. [Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions](https://mdpi-res.com/d_attachment/ijms/ijms-23-00836/article_deploy/ijms-23-00836.pdf). Int J Mol Sci. 2022;23(2):836. | | | | | | | 69/296  (2021) | | 21 (2021) | | 6.208  (2021) |
| 10. | Božić A, Gajdobranski Đ, Brestovački-Svitlica B, Medić-Peričević S, **Mikov M**, Vasović V, et al. The prevalence of low back pain among nurses in Serbia. Work. 2022;71(1):249-54. doi: 10.3233/WOR-205144 | | | | | | | 246/302 (2021) | | 23 (2021) | | 1.803 (2021) |
| 11. | Mooranian A, Ionescu CM, Walker D, Jones M, Wagle SR, Kovačević B, et al ... **Mikov M**, Al-Salami H. [Single-cellular biological effects of cholesterol-catabolic bile acid-based nano/micro capsules as anti-inflammatory cell protective systems](https://mdpi-res.com/d_attachment/biomolecules/biomolecules-12-00073/article_deploy/biomolecules-12-00073-v2.pdf). Biomolecules. 2022;12(1):73. | | | | | | | 75/296  (2021) | | 21 (2021) | | 6.064  (2021) |
| 12. | Pavlović N, Bogićević I, Zaklan D, Djanić M, Goločorbin-Kon S, Al-Salami H, **Mikov M**. [Influence of bile acids in hydrogel pharmaceutical formulations on dissolution rate and permeation of clindamycin hydrochloride](https://mdpi-res.com/d_attachment/gels/gels-08-00035/article_deploy/gels-08-00035.pdf). Gels. 2022;8(1):35. | | | | | | | 22/90  (2021) | | 21 (2021) | | 4.432  (2021) |
| 13. | Rajsic I, Lazarevic S, Djanic M, Al-Salami H, Mooranian A, Vukmirovic SN, **Mikov M**, Goločorbin-Kon S. Plasma distribution of Methotrexate and its polyglutamates in pediatric acute lymphoblastic leukemia: Preliminary Insights. Eur J Drug Metab Pharmacokinet. 2022;47(1):127-34. doi: 10.1007/s13318-021-00726-9 | | | | | | | 200/279 (2021) | | 23 (2021) | | 2.569 (2021) |
| 14. | Teofilović BD, Goločorbin-Kon S, Stilinović N, Grujić-Letić N, Rašković A, Mooranian A, et al ... **Mikov M**. [Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study](https://www.nature.com/articles/s41598-021-01713-5.pdf). Sci Rep. 2021;11(1):22123. | | | | | | | 19/73 | | 21 | | 4.996 |
| 15. | Mooranian A, Ionescu CM, Wagle SR, Kovačević B, Walker D, Jones M, et al ... **Mikov M**, Al-Salami H. [Polyelectrolytes Formulated with Primary Unconjugated Bile Acid Optimised Pharmacology of Bio-Engineered Implant](https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-01713/article_deploy/pharmaceutics-13-01713.pdf). Pharmaceutics. 2021;13(10):1713. | | | | | | | 39/279 | | 21 | | 6.525 |
| 16. | Mooranian A, Carey L, Ionescu CM, Walker D, Jones M, Wagle SR, Kovačević B, et al... **Mikov M**, Al-Salami H. [The Effects of Accelerated Temperature-Controlled Stability Systems on the Release Profile of Primary Bile Acid-Based Delivery Microcapsules](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538769/pdf/pharmaceutics-13-01667.pdf). Pharmaceutics. 2021;13(10):1667. | | | | | | | 39/279 | | 21 | | 6.525 |
| 17. | Mooranian A, Foster T, Ionescu CM, Carey L, Walker D, Jones M, et al ... **Mikov M**, Al-Salami H. [The effects of primary unconjugated bile acids on nanoencapsulated pharmaceutical formulation of hydrophilic drugs: pharmacological implications](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550211/pdf/dddt-15-4423.pdf). Drug Des Devel Ther. 2021;15:4423-34. | | | | | | | 102/279 | | 22 | | 4.319 |
| 18. | Smiesko GM, Gusman VP, Banović PZ, **Mikov M**. [Probiotics and fecal bacteriotherapy: the line between deception and treatment](https://scindeks-clanci.ceon.rs/data/pdf/0042-8450/2021/0042-84502109994S.pdf). Vojnosanit Pregl. 2021;78(9):994-9. | | | | | | | 168/172 | | 23 | | 0.245 |
| 19. | Topic-Vucenovic V, Rajkovaca Z, Jelic D, Stanimirovic D, **Mikov M**, Miljkovic BR, et al. [Population exposure-response model of 131I in patients with benign thyroid disease](https://reader.elsevier.com/reader/sd/pii/S0928098721002451?token=D5A2194A5F676DF2DC16B21B40C8BA6153DDA1105DBFFE9F60E95D5D44455D063161D6B28F034B62CEE4FC89ADE15866&originRegion=eu-west-1&originCreation=20220412103602). Eur J Pharm Sci. 2021;165:105942. | | | | | | | 74/279 | | 21 | | 5.112 |
| 20. | Mooranian A, Ionescu CM, Wagle SR, Kovačević B, Walker D, Jones M, et al ... **Mikov M**, ... Al-Salami H. [Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study](https://mdpi-res.com/d_attachment/cells/cells-10-02437/article_deploy/cells-10-02437.pdf). Cells. 2021;10(9):2437. | | | | | | | 51/194 | | 21 | | 7.666 |
| 21. | Wagle SR, Kovačević B, Ionescu CM, Walker D, Jones M, Carey L, et al ... **Mikov M**, ... Al-Salami H. [Pharmacological and Biological Study of Microencapsulated Probucol-Secondary Bile Acid in a Diseased Mouse Model](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400495/pdf/pharmaceutics-13-01223.pdf). Pharmaceutics. 2021;13(8):1223. | | | | | | | 39/279 | | 21 | | 6.525 |
| 22. | Mooranian A, Ionescu CM, Wagle SR, Kovačević B, Walker D, Jones M, et al ... **Mikov M**, Atlas MD, Al-Salami H. [Probucol Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions](https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-01304/article_deploy/pharmaceutics-13-01304.pdf). Pharmaceutics. 2021;13(8):1304. | | | | | | | 39/279 | | 21 | | 6.525 |
| 23. | Mooranian A, Foster T, Ionescu CM, Walker D, Jones M, Wagle SR, et al ... **Mikov M**, Al-Salami H. [Enhanced Bilosomal Properties Resulted in Optimum Pharmacological Effects by Increased Acidification Pathways](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398365/pdf/pharmaceutics-13-01184.pdf). Pharmaceutics. 2021;13(8):1184. | | | | | | | 39/279 | | 21 | | 6.525 |
| 24. | Rajsic I, Pavlovic N, Milijasevic B, Vukmirovic S, Spasic DT, Zigic M, et al ... **Mikov M**. [The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection](http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84501900126R.pdf). Vojnosanit Pregl. 2021;78(7):708-15. | | | | | | | 168/172 | | 23 | | 0.245 |
| 25. | Mooranian A, Jones M, Ionescu CM, Walker D, Wagle SR, Kovačević B, et al ... **Mikov M**, Al-Salami H. [Advancements in Assessments of Bio-Tissue Engineering and Viable Cell Delivery Matrices Using Bile Acid-Based Pharmacological Biotechnologies](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308343/pdf/nanomaterials-11-01861.pdf). Nanomaterials (Basel). 2021;11(7):1861. | | | | | | | 37/161 | | 21 | | 5.719 |
| 26. | Chester J, Johnston E, Walker D, Jones M, Ionescu CM, Wagle SR, et al ... **Mikov M**, ... Al-Salami H. [A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology](https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-01041/article_deploy/pharmaceutics-13-01041-v2.pdf). Pharmaceutics. 2021;13(7):1041. | | | | | | | 39/279 | | 21 | | 6.525 |
| 27. | MircioiuC, Anuta V, **Mikov M**, Nicolescu A, Voicu VA. [Editorial:Pharmacokinetic Evaluation and Modeling of Clinically Significant Drug Metabolites](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172789/pdf/fphar-12-693922.pdf). Front Pharmacol. 2021;12:693922. | | | | | | | 50/279 | | 21 | | 5.988 |
| 28. | Djanic M, Pavlovic N, Stanimirov BG, Lazarevic S, Vukmirovic S, Al-Salami H, **Mikov M**. [PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids](https://reader.elsevier.com/reader/sd/pii/S0928098720304565?token=FC568A986CA33D20EAD5889F1B2169CF51A218772B21ED04D056DC75806A96922F076E7826167BBC5053B23C90E5A559&originRegion=eu-west-1&originCreation=20220412111420). Eur J Pharm Sci. 2021;158:105668. | | | | | | | 74/279 | | 21 | | 5.112 |
| 29. | Gvoic M, Vukmirovic S, Al-Salami H, Mooranian A, **Mikov M**, Stankov K. Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review. Pharm Dev Technol. 2021;26(6):617-33. doi: 10.1080/10837450.2021.1916032 | | | | | | | 119/279 | | 22 | | 3.915 |
| 30. | Medić-Peričević S, Mikov I, Glavaški-Kraljević M, Božić A, Vasović V, **Mikov M**. The effects of aging and driving experience on reaction times of professional drivers. Work. 2020;66(2):405-19. doi: 10.3233/WOR-203181 | | | | | | | 235/294 | | 23 | | 1.505 |
| 31. | Sekuljica S, Guzsvany V, Anojčić J, Hegedus T, **Mikov M**, Kalcher K. [Imidazolium-based liquids as modifiers of carbon paste electrodes for trace-level voltametric determination of dopamine in pharmaceutical preparations.](https://pdf.sciencedirectassets.com/271359/1-s2.0-S0167732220X00079/1-s2.0-S0167732219364396/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEL7%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIQD53K4fBtpJNR2HHIZ0WDm474Ri4CQM3uSWXbLxqAllzQIgNdbAN%2BzMLEP) J Mol Liq. 2020;306:112900. | | | | | | | 4/37 | | 21 | | 6.165 |
| 32. | Stojanović G, Nikodinović-Runić J, Švenderman S, Kojić T, Radovanović M, **Mikov M**, Randjelović D. [Comprenhesive charcterization of elastomeric polyhydroxyalkanoate and in senzor applications](https://ezproxy.nb.rs:2055/science/article/pii/S0928493119340196?via%3Dihub). Mat Sci Eng C-BIOS S. 2020;115:11109. | | | | | | | 7/40 | | 21 | | 7.328 |
| 33. | Kecman S, Škrbić R, Badnjević-Čengić A, Mooranian A, Al-Salami H, **Mikov M**, Goločorbin-Kon S. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. Technol Health Care. 2020;28:3:325-35. | | | | | | | 102/109 | | 23 | | 1.285 |
| 34. | Wagle S, Walker D, Kovačević B, Gedway A, **Mikov M**, Goločorbin-Kon S, Mooranian A, Al-Salami H[. Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies](https://ezproxy.nb.rs:2171/articles/s41598-020-64355-z.pdf). Sci Rep. 2020;10:7715. | | | | | | | 17/73 | | 21 | | 4.379 |
| 35. | Maksimović V, Pavlović-Popović Z, Vukmirović S, Cvejić J, Mooranian A, Al-Salami H, M**ikov M**, Goločorbin-Kon S. [Molecular mechanism of action and pharmacokinetic properties of metotrexate](https://ezproxy.nb.rs:2078/content/pdf/10.1007/s11033-020-05481-9.pdf). Mol Biol Rep. 2020;47:4699-708. | | | | | | | 239/297 | | 23 | | 2.316 |
| 36. | Mooranian A, Zamani N, Ionescu C, Takechi R, Luna G, **Mikov M**, Goločorbin-Kon S, Kovačević B, Al-Salami. Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflamation. Pharmacol Rep. 2020;72(2):368-378. | | | | | | | 163/275 | | 22 | | 3.024 |
| 37. | Mooranian A, Wagle S, Kovačević B, Takechi R, Mamo J, Lam V, Watts G, **Mikov M**, Goločorbin-Kon S, Stojanović G, Al-Salami H, Al-Salami H. [Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study](https://ezproxy.nb.rs:2171/articles/s41598-019-53999-1.pdf). Sci Rep. 2020;10:106. | | | | | | | 17/73 | | 21 | | 4.379 |
| 38. | Parezanović-Švonja G, Lalić-Popović M, Goločorbin-Kon S, Todorović N, Pavlović N, **Mikov M**. [In vitro comparative quality evaluation of non-expired and ten years expired lamotrigine immediate-release tablet formulations - pilot study.](http://dissolutiontech.com/issues/202002/DT202002_A02.pdf) Dissolut Technol. 2020;27:14-20. | | | | | | | 258/275 | | 23 | | 0.978 |
| 39. | **Mikov M**, Pavlović N, Stanimirov B, Djanić M, Goločorbin-Kon S, Stankov K, Al-Salami H. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. Eur J Drug Metab Pharmakokinet. 2020;45(1):1-14. | | | | | | | 201/275 | | 23 | | 2.441 |
| 40. | Mooranian A, Zamani N, **Mikov M**, Goločorbin-Kon S, Stojanović G, Arfuso F, Kovačević B, Al-Salami H. [A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds](https://pdf.sciencedirectassets.com/278665/1-s2.0-S1319016420X00028/1-s2.0-S1319016419301689/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEF4aCXVzLWVhc3QtMSJGMEQCICkM4xOwHmx8ZICfRyvUjdWnmSaz0yn32XYSdV%2FqeJwgAiBFtW5gTBlMWGTHqwHoMjWUHa%2BL9AeUH6n5RTQirJ4P3). Saudi Pharm J. 2020;28(2):165-71. | | | | | | | 65/267  (2018) | | 21  (2018) | | 3.643  (2018) |
| 41. | Pavlović N, Djanić M, Stanimirov B, Goločorbin-Kon S, Stankov K, Lalić-Popović M, **Mikov M**. In silico discovery of resveratrol analogues as potential agents in treatment of metabolic disorders. Curr Pharm Design. 2019;35:3776-83. | | | | | | | 148/267  (2018) | | 22 (2018) | | 2.412  (2018) |
| 42. | Anojčić J, Guzsvany V, Konya Z, **Mikov M**. [Rapid, trace-level direct cathodic voltammetric determination of dopamine by oxidized multiwalled carbon nanotube-modified carbon paste electrode in selected samples of pharmaceutical importance](https://ezproxy.nb.rs:2078/content/pdf/10.1007/s11581-019-03156-5.pdf). Ionics. 2019;25(12):6093-6106. | | | | | | | 34/69 | | 22 | | 2.394 |
| 43. | Mooranian A, Zamani N, Luna G, Al-Sallami H, **Mikov M**, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. [Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model.](https://pubmed.ncbi.nlm.nih.gov/31557068/) Pharm Dev Technol. 2019; 24(10):1272-77. | | | | | | | 153/267 (2018) | | 22 (2018) | | 2.347 (2018) |
| 44. | Djanić M, Stanimirov B, Pavlović N, Vukmirović S, Lazić J, Al-Salami H, **Mikov M**. [Transport and biotransformation of gliclazide and](https://www.frontiersin.org/articles/10.3389/fphar.2019.01083/full)[the effect of deoxycholic acid in a probiotic bacteria model](https://www.frontiersin.org/articles/10.3389/fphar.2019.01083/full). Front Pharmacol. 2019;10:1083. | | | | | | | 52/270 | | 21 | | 4.225 |
| 45. | Lazarević S, Đanić M, Goločorbin-Kon S, Al-Salami H, **Mikov M**.  [Semisynthetic bile acids: a new therapeutic option for metabolic syndrome](https://reader.elsevier.com/reader/sd/pii/S1043661819302786?token=0AA8487A42CEA9758CB784474CA8FA375A9427BB87B26AA330039E91DD52AFB11273FBB008F7DA3463F84C0CA852B5C0). Pharmacol Res. 2019;146:104333. | | | | | | | 19/270 | | 21a | | 5.893 |
| 46.. | Parezanović GŠ, Lalic-Popovic M, Golocorbin-Kon S, Vasovic V, Milijašević B, Al-Salami H, **Mikov M**. [Environmental transformation of pharmaceutical formulations: a scientific review](https://link.springer.com/content/pdf/10.1007%2Fs00244-019-00630-z.pdf). Arch Environ Contam Toxicol. 2019;77(2):151-61. | | | | | | | 133/265 | | 22 | | 2.400 |
| 47. | Šarenac T, **Mikov M**. [Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558109/pdf/fphar-10-00484.pdf). Front Pharmacol. 2019;10:484. | | | | | | | 52/270 | | 21 | | 4.225 |
| 48. | Kovacevic T, Miljkovic B, **Mikov M**, Stojisavljevic Satara S, Dragic S, Momcicevic D, Kovacevic P. [The effect of hypoalbuminemia on the therapeutic concentration and dosage of vancomycin in critically ill septic patients in low-resource countries](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537498/pdf/10.1177_1559325819850419.pdf). Dose Response. 2019;17(2):1559325819850419. | | | | | | | 159/270 | | 22 | | 2.438 |
| 49. | Janković N, Trifunović Ristovski J, Vraneš M, Tot A, Petronijević J, Joksimović N, Stanojković T, Đorđić Crnogorac M, Petrović N, Boljević I, Matić IZ, Bogdanović GA, **Mikov M**, Bugarčić Z. [Discovery of the Biginelli hybrids as novel caspase-9 activators in apoptotic machines: lipophilicity, molecular docking study, influence on angiogenesis gene and miR-21 expression levels](https://reader.elsevier.com/reader/sd/pii/S0045206818312598?token=38B63CA121D61FA4539E3DD7C0F6B705A9AA174CEF15A1B715C5F99DF48A0DF3C3986FECB5E2CB40FFA87012D3E4AE08). Biorg Chem. 2019;86:569-82. | | | | | | | 8/57 | | 21 | | 4.831 |
| 50. | Mooranian A, Zamani N, Takechi R, Luna G, **Mikov M**, Goločorbin-Kon S, Elnashar M, Arfuso F, Al-Salami H. [An in vivo pharmacological study: variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449070/pdf/pone.0214984.pdf). PLoS ONE. 2019;14(4):e0214984. | | | | | | | 15/64  (2017) | | 21  (2017) | | 2.766  (2017) |
| 51. | Rašković A, Bukumirović N, Paut Kusturica M, Milić N, Čabarkapa V, Borišev I, Čapo I, Miljković D, Stilinović N, **Mikov M**. [Hepatoprotective and antioxidant potential of Pycnogenol® in acetaminophen-induced hepatotoxicity in rats](https://onlinelibrary.wiley.com/doi/epdf/10.1002/ptr.6251). Phytother Res. 2019;33(3):631-39. | | | | | | | 58/270 | | 21 | | 4.087 |
| 52. | Mooranian A, Zamani N, Takechi R, Al-Sallami H, **Mikov M**, Goločorbin-Kon S, Kovacevic B, Arfuso F, Al-Salami H. [Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes](https://www.tandfonline.com/doi/pdf/10.1080/21691401.2018.1511572). Artif Cells Nanomed Biotechnol. 2018;46(sup3):S748-54. | | | | | | | 3/33  (2016) | | 21a  (2016) | | 5.605  (2016) |
| 53. | Mooranian A, Zamani N, **Mikov M**, Goločorbin-Kon S, Stojanovic G, Arfuso F, Al-Salami H. [Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses](https://www.tandfonline.com/doi/pdf/10.1080/21691401.2018.1511571?needAccess=true). Artif Cells Nanomed Biotechnol. 2018;46(sup3):S741-7. | | | | | | | 3/33  (2016) | | 21a  (2016) | | 5.605  (2016) |
| 54. | Goločorbin-Kon S, **Mikov M**, Cvejić-Hogervorst JM, Al-Salami H, Maksimović V[. Dried blood spot: utilising dry blood for pharmacokinetic investigations - an old method with great future for therapeutic drug monitoring](http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700046G.pdf). Vojnosanit Pregl. 2018;75(12):1222-5. | | | | | | | 155/160 | | 23 | | 0.272 |
| 55. | Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, **Mikov M**. [Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome](https://www.frontiersin.org/articles/10.3389/fphar.2018.01382/full). Front Pharmacol. 2018;9:1382. | | | | | | | 59/267 | | 21 | | 3.845 |
| 56. | Pavlović N, Goločorbin-Kon S, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, **Mikov M**. [Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles](https://www.frontiersin.org/articles/10.3389/fphar.2018.01283/full). Front Pharmacol. 2018;9:1283. | | | | | | | 59/267 | | 21 | | 3.845 |
| 57. | Šarenac TM, **Mikov M**. [Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients](https://www.frontiersin.org/articles/10.3389/fphar.2018.00939/full). Front Pharmacol. 2018;9:939. | | | | | | | 59/267 | | 21 | | 3.845 |
| 58. | Dragojević-Simić V, Kovačević A, Jaćević V, Rančić N, Djordjević S, Kilibarda V, **Mikov M**, Bokonjić D. Bioequivalence study of two formulations of itraconazole 100 mg capsules in healthy volunteers under fed conditions: a randomized, three-period, reference-replicated, crossover study. Expert Opin Drug Metab Toxicol. 2018;14(9):979-88. | | | | | | | 74/267 | | 21 | | 3.487 |
| 59. | Ćatić-Djordjević A, Pavlović I, Pavlović D, Stefanović N, **Mikov M**, Cvetković T, Veličković-Radovanović R. Evaluation of gender-based limited sampling methods for tacrolimus exposure after renal transplantation using the Monte Carlo simulation. Pharmazie. 2018;73(8):482-5. | | | | | | | 245/267 | | 23 | | 0.820 |
| 60. | Rančić N, Lozanov-Crvenković Z, **Mikov M**, Vavić N, Dragojević-Simić V. [An equation for tacrolimus daily dose calculation in renal transplant patients - simple and cost saving](https://scindeks-clanci.ceon.rs/data/pdf/0042-8450/2018/0042-84501807739R.pdf)? Vojnosanit Pregl. 2018;75(7):739-40. | | | | | | | 155/160 | | 26 | | 0.272 |
| 61. | Vasović V**,** Stilinović N, Vukmirović S, Mikov I, Ćalasan J, **Mikov M.** [The effect of Aminophylline on quinidine passage into the central nervous system of rats](https://pdfs.semanticscholar.org/a69f/38f863de54d626a7b1c524997bc3e7eb2596.pdf?_ga=2.6188339.160643447.1599204101-1499355688.1599204101). Indian J Pharm Educ Res. 2018;52(1):146-50. | | | | | | | 262/267 | | 23 | | 0.425 |
| 62. | Trifunovic-Ristovski J, Jankovic N, Borcic V, Sankalp J, Bugarcic Z, **Mikov M**. [Evaluation of antimicrobial activity and retention behaviour of newly synthesized vanilidene derivates of Meldrums acid isung QSRR approach](https://reader.elsevier.com/reader/sd/3BA8FE1DDAA8577B25BE642C8BF78A38561F90197E3A7F957CC22C013F145777AEC14D36428A2AD9696C87DFDE1FD318). J Pharm Biomed Anal. 2018;155:42-9. | | | | | | | 24/84 | | 21 | | 2.983 |
| 63. | Trifunović J, Borčić V, Vukmirovic S, **Mikov M**. [Pharmacokinetic profiling of some carbohydrate derivates and their structure activity relationship evaluation](https://open.uns.ac.rs/bitstream/123456789/1622/1/Trifunovic%20et%20al%2C%202018.pdf). Curr Pharm Anal. 2018;14(3):262-70. | | | | | | | 244/267 | | 23 | | 0.829 |
| 64. | Rancic N, Vavic N, Cikota-Aleksic B, Magic Z, **Mikov M**, Bokonjic D, Segrt Z, Dragojevic-Simic V. [The relationship between tacrolimus concentration-dose ratio and genetic polymorphism in patients subjected to renal transplantation](http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501600329R.pdf). Vojnosanit Pregl. 2018;75(2):147-53. | | | | | | | 155/160 | | 23 | | 0.272 |
| 65. | Kamal T, Sarfraz M, Arafat M, **Mikov M**, Rahman N. [Cross-linked guar gum and sodium borate based microspheres as colon-targeted anticancer drug delivery systems for 5-fluorouracil](https://www.researchgate.net/publication/321419667_Cross-linked_guar_gum_and_sodium_borate_based_microspheres_as_colon-targeted_anticancer_drug_delivery_systems_for_5-fluorouracil/link/5a2116110f7e9b4d19283105/download). Pak J Pharm Sci.  2017;30(6)suppl1:2329-36. | | | | | | | 241/261 | | 23 | | 0.804) |
| 66. | **Mikov M**, Đanić M, Pavlović N, Stanimirov B**,** Goločorbin-Kon S, Stankov K, Al-Salami H. [Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics](https://link.springer.com/article/10.1007%2Fs13318-017-0441-y). Eur J Drug Metab Pharmacokinet. 2018;43(3):269-80. | | | | | | | 221/21 (2017) | | 23 (2017) | | 1.362  (2017) |
| 67. | **Mikov M**, Đanić M, Pavlović N, Stanimirov B, Goločorbin-Kon S, Stankov K, Al-Salami H. [The role of drug metabolites in the inhibition of cytochrome P450 Enzymes](https://link.springer.com/article/10.1007%2Fs13318-017-0417-y). Eur J Drug Metab Pharmacokinet. 2017;42(6):881-90. | | | | | | | 221/21 | | 23 | | 1.362 |
| 68. | Trifunović J, Borčić V, Vukmirovic S, **Mikov M**. [Structural insights into anticancer activity of D-ring modified estrone derivatives using their lipophilicity in estimation of SAR and molecular docking studies.](https://www.ncbi.nlm.nih.gov/pubmed/29068177) Drug Test Anal. 2017;9(10):1542-8. | | | | | | | 18/80 | | 21 | | 2.993 |
| 69. | Stoyanova T, Lessigiarska I, **Mikov M**, Pajeva I, Yanev S. [Xanthates as useful probes for testing the active sites of cytochromes P450 4A11 and 2E1.](https://www.frontiersin.org/articles/10.3389/fphar.2017.00672/full) Front Pharmacol. 2017;8:672. doi:10.3389/fphar.2017.00672. | | | | | | | 48/261 | | 21 | | 3.831 |
| 70. | Arafat M, Kirchhoefer C, **Mikov M**, Sarfraz M, Lobenberg R. [Nanosized liposomes containing bile salt: a vesicular nanocarrier for enhancing oral bioavailability of BCS class III drug](https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/viewFile/29340/21365). J Pharm Pharma Sci. 2017;20(0):305-18. | | | | | | | 143/261 | | 22 | | 2.333 |
| 71. | Goločorbin-Kon **S**, Calasan J, Milijasevic B, Vukmirovic S, Lalic-Popovic M, **Mikov M**, Al-Salami H. [High-loading dose of microencapsulated gliclazide formulation exerted a hypoglycaemic effect on type 1 diabetic rats and incorporation of a primary deconjugated bile acid, diminished the hypoglycaemic antidiabetic effect](https://link.springer.com/content/pdf/10.1007%2Fs13318-017-0415-0.pdf). Eur J Drug Metab Pharmacokinet. 2017;42(6):1005-11. | | | | | | | 221/261 | | 23 | | 1.362 |
| 72. | Mathavan S, **Mikov M**,Goločorbin-Kon S, Al-Salami H. [Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects](https://ac.els-cdn.com/S0928098717302695/1-s2.0-S0928098717302695-main.pdf?_tid=33e083c2-ce9d-11e7-8461-00000aab0f6c&acdnat=1511256203_cac717e2567fa55379e962c72dfcaadf). Eur J Pharm Sci. 2017;106:1-9. | | | | | | | 68/261 | | 21 | | 3.466 |
| 73. | Arafat M, Kirchhoefer C, **Mikov M**[. Mixed micelles loaded with bile salt: an approach to enhance intestinal transport of the BCS class III drug cefotaxime in rats](https://link.springer.com/content/pdf/10.1007%2Fs13318-016-0375-9.pdf). Eur J Drug Metab Pharmacokinet. 2017;42(4):635-645. | | | | | | | 221/261 | | 23 | | 1.362 |
| 74. | Trifunovic J, Borcic V, Vukmirovic S, Vasovic V, **Mikov M**. Bile acids and their oxo derivatives: environmentally safe materials for drug design and delivery. Drug Chem Toxicol. 2017;40(4):397-405. | | | | | | | 89/166  (20165) | | 22  (2016) | | 1.732  (2016) |
| 75. | Pavlovic N, Stanimirov B, **Mikov M**. Bile acids as novel pharmacological agents: the interplay between gene polymorphisms, epigenetic factors and drug response. Curr Pharm Des. 2017;23(1):187-215. | | | | | | | 74/255  (2015) | | 21  (2015) | | 3.052  (2015) |
| 76. | Trifunovic J, Borcic V, **Mikov M**. [Bile acids and their oxo derivates: potential inhibitors of carbonic anhydrase I and II, androgen receptor antagonists and CYP3A4 substrates](http://onlinelibrary.wiley.com/doi/10.1002/bmc.3870/pdf). Biomed Chromatogr. 2017;31(5):1-8. | | | | | | | 46/80 | | 22 | | 1.688 |
| 77. | Vukmirovic S, Kusturica MP, Milijasevic B, Trifunovic J, Tomas A, **Mikov M**. [Fermentation potentiates antimotility properties of Chamomile Ligulate flower extracts](http://www.ijpsonline.com/articles/fermentation-potentiates-antimotility-properties-of-chamomile-ligulate-flower-extracts.html). Indian J Pharm Sci. 2016;78(5):692-5. | | | | | | | 240/256 | | 23 | | 0.660 |
| 78. | Trifunović J, Borčić V, Vukmirović S, Mikov M. [Assessment of the pharmacokinetic profile of novel s-triazine derivatives and their potential use in treatment of Alzheimer disease](http://ac.els-cdn.com/S0024320516306324/1-s2.0-S0024320516306324-main.pdf?_tid=2fd670f2-621e-11e7-a02f-00000aab0f6b&acdnat=1499326925_847e48092aac139b89f1d94347a5ec4a). Life Sci. 2017;168:1-6. | | | | | | | 78/261 | | 21 | | 3.234 |
| 79. | Joksic-Mazinjanin R, Joksic M, Vasovic V, **Mikov M,** Saravolac S, Djuricin A, Saponja P. ([Location of out-of-hospital cardiac arrest as a determinant in the survival of patients](http://www.srpskiarhiv.rs/dotAsset/51921). Srp Arh Celok Lek. 2016;144(9-10):485-9. | | | | | | | 146/154 | | 23 | | 0.253 |
| 80. | Lalic-Popovic M,  Paunkovic J, Grujic Z, Golocorbin-Kon S, Vasovic V, Al-Salami H, **Mikov M**. [The effect of diabetes and hypertension on the placental permeation of the hydrophilic drug, ranitidine](http://ac.els-cdn.com/S0143400416305926/1-s2.0-S0143400416305926-main.pdf?_tid=8a5e73dc-5808-11e7-927d-00000aab0f02&acdnat=1498218116_940e5e8f53803f42e2ca2ac04a1f6b3c). Placenta. 2016;48:144-50. | | | | | | | 19/80 | | 21 | | 2.759 |
| 81. | Trifunović J, Borčić V, Vukmirović S, **Mikov M**, Goločorbin-Kon S. [Retention data of bile acids and their oxo derivates in characterization of pharmacokinetic properties and in silico ADME modeling](http://ac.els-cdn.com/S0928098716302652/1-s2.0-S0928098716302652-main.pdf?_tid=c5b28a98-5a3a-11e7-a52a-00000aab0f02&acdnat=1498459593_d4142cd0e3a72b1f0fcfb02005c19731). Eur J Pharm Sci 2016;92:194-202. | | | | | | | 54/256 | | 21 | | 3.756 |
| 82. | Suvajdžić Lj, Gigov S, Rašković A, Stojanović S, Bekut A, Milanov D, Čanak I, Golocorbin-Kon S, **Mikov M**. [Influence of the sodium salt of 3a,7a-dihydroxy-12-oxo-5-cholanate on antimicrobial activity of ampicillin in vitro](http://www.ufrgs.br/actavet/44/PUB%201397.pdf). Acta Sci Vet 2016; 44(1397): 1-6. | | | | | | | 119/136 | | 23 | | 0.234 |
| 83. | Vavic N, Rancic N, Cikota-Aleksic B, Magic Z, Cimesa J, Obrencevic K, Radojevic M, **Mikov M**, Dragojevic-Simic V. [The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation](http://www.doiserbia.nb.rs/img/doi/0042-8450/2016/0042-84501600016V.pdf). Vojnosanit Pregl. 2016;73(7):663-7. | | | | | | | 139/154 | | 23 | | 0.367 |
| 84. | Djanic M, Pavlovic N, Stanimirov B, Stojancevic T, Golocorbin-Kon S, Bojic G, **Mikov M**. [Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria](https://www.researchgate.net/profile/Maja_Danic_stojancevic/publication/295909947_Docking-based_preliminary_study_on_the_interactions_of_bile_acids_with_drugs_at_the_transporter_level_in_intestinal_bacteria/links/56d4376a08ae2ea08cf8e1d2/Docking-based-prel). Eur Rev Med Pharmacol Sci 2016;20(3):553-60. | | | | | | | 180/256 | | 23 | | 1.778 |
| 85. | Tomić Z, Tomas A, Vukmirović S, **Mikov M**, Horvat O, Tomić N, Sabo A. Do we bury antibacterials when launching? Cefaclor example. J Pharm Sci. 2016;105(3):1295-300. | | | | | | | 129/256 | | 22 | | 2.415 |
| 86. | Đanić M, Pavlović N, Stanimirov B, Vukmirović S, Nikolić K, Agbaba D,**Mikov M**. [The influence of bile salts on the distribution of simvastatin in the octanol/buffer system](https://www.researchgate.net/publication/280307444_The_influence_of_bile_salts_on_the_distribution_of_simvastatin_in_the_octanolbuffer_system). Drug Dev Ind Pharm. 2016;42(4):661-7. | | | | | | | 141/256 | | 23 | | 2.295 |
| 87. | Lalic-Popovic M, Paunkovic J, Grujic Z, Golocorbin-Kon S, Milasinovic Lj, Al-Salami H, **Mikov M**. [Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes](http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12288/pdf). [J Diabetes.](http://www.ncbi.nlm.nih.gov/pubmed/25800069) 2016;8(2):238-45. | | | | | | | 70/138 | | 22 | | 3.039 |
| 88. | Negrulj R, Mooranian A, Chen-Tan N, Al-Sallami HS, **Mikov M**, Golocorbin-Kon S, Fakhoury M, Watts GF, Arfuso F, Al-Salami H. Swelling, mechanical strenght, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 2016;44(5):1290-7. | | | | | | | 4/77 | | 21a | | 5.605 |
| 89. | Raskovic A, Pavlovic N, Kvrgic M, Sudji J, Mitic G, Capo I, **Mikov M**. [Effects of pharaceutical formulations containing thyme on carbon tetrachloride-induced liver injury in rats](http://download.springer.com/static/pdf/582/art%253A10.1186%252Fs12906-015-0966-z.pdf?originUrl=http%3A%2F%2Fbmccomplementalternmed.biomedcentral.com%2Farticle%2F10.1186%2Fs12906-015-0966-z&token2=exp=1496405050~acl=%2Fstatic%2Fpdf%2F582%2Fart%25253A10.118). BMC Complement Altern Med. 2015; 15(1):442. | | | | | | | 5/24 | | 21 | | 1.987 |
| 90. | Mooranian A, Negrulj R, **Mikov M**, Golocorbin-Kon S, Arfuso F, Al-Sallami H. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study. J Microencapsul. 2015;32(6):589-97. | | | | | | | 31/72 | | 22 | | 1.631 |
| 91. | Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciaretta J, Chen-Tan N, Mukkur TK, **Mikov M**, Lalić-Popović M, Stojancevic M, Golocorbin-Kon S, Al-Sallami H. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20(6):702-9. | | | | | | | 188/255 | | 23 | | 1.566 |
| 92. | Paut Kusturica M, Tomić Z, Bukumirić Z, Horvat O, Pavlović N, **Mikov M**, Sabo A. [Antibiotics in Serbian households: a source of potential health and environmental threats](http://apps.szu.cz/svi/cejph/archiv/2015-2-04-full.pdf)? Cent Eur J Public Health. 2015;23(2):114-8. | | | | | | | 242/260 | | 23 | | 0.525 |
| 93. | Sabo A, Tomas A, Tomić N, **Mikov M**, Horvat O, Popović R, Tomić Z. [Pharmacokinetic/pharmacodynamic based dosing of ciprofloxacin in complicated urinary tract infections](http://banglajol.info/index.php/BJP/article/view/23604/16493). Bangladesh J Pharmacol. 2015;10(3):621-6. | | | | | | | 235/255 | | 23 | | 0.671 |
| 94. | Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, **Mikov M**, Golocorbin-Kon S, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151-6. | | | | | | | 31/72 | | 22 | | 1.631 |
| 95. | Suvajdzic Lj, Stojakovic N, **Mikov M**, Stoisavljevic Satara S, Skrbic R, Vidic B, Dankuc D, Suvajdzic Z. [Influence of bile acids on rat gut microflora deterioration induced by oral ampicillin treatment](http://niv.ns.ac.rs/full/inflvb15.pdf). Acta Sci Vet. 2015;43:1282. | | | | | | | 125/138 | | 23 | | 0.198 |
| 96. | Rančić N, Dragojević-Simić V, Vavić N, Kovačević A, Šegrt Z, Drašković-Pavlović B, **Mikov M**. [Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication](http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501500005R.pdf). Vojnosanit Pregl. 2015;72(9):813-22. | | | | | | | 134/155 | | 23 | | 0.355 |
| 97. | Mooranian A, Negrulj R, Al-Sallami HS, Fang ZX, **Mikov M**, Golocorbin-Kon S, et al. [Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes](https://link.springer.com/content/pdf/10.1208%2Fs12249-014-0205-9.pdf). AAPS PharmSciTech 2015;16(1):45-52. | | | | | | | 159/255 | | 23 | | 1.954 |
| 98. | Velickovi-Radovanovic R, **Mikov M**, Catic-Djordjevic A, Stefanovic N, Mitic B, Paunovic G, Cvetkovic T. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients. Eur J Drug Metab Pharmacokinet. 2015;40(1):95-102. | | | | | | | 176/255 | | 23 | | 1.680 |
| 99. | Stanimirov B, Stankov K, **Mikov M**. [Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases](http://www.hbpdint.com/EN/Y2015/V14/I1/18). Hepatobiliary Pancreat Dis Int. 2015;14(1):18-33. | | | | | | | 66/79 | | 23 | | 1.724 |
| 100. | Raskovic A, Milanovic I, Pavlovic N, Milijasevic B, Ubavic M, **Mikov M**. [Analgesic effects of rosemary essential oil and its interactions with codeine and paracetamol in mice](http://www.europeanreview.org/wp/wp-content/uploads/165-172.pdf). Eur Rev Med Pharmacol Sci. 2015;19(1):165-72. | | | | | | | 186/255 | | 23 | | 1.575 |
| 101. | Stankov K, Popović S, **Mikov M**. C-kit signaling in cancer treatment. Curr Pharm Des. 2014;20(17):2849–80. | | | | | | | 63/255 | | 21 | | 3.452 |
| 102. | Milijasevic B, Stefanovic D, Lalic-Popovic M, Tomic Z, Kolarovic J, Lalosevic D, **Mikov M**. Acute toxic effects of single dose dacarbazine: hematological and histological changes in an animal model. Biotech Histochem. 2014;89(8):583-90. | | | | | | | 113/163 | | 23 | | 1.444 |
| 103. | Vavic N, Rancic N, Dragojevic-Simic V, Draskovic-Pavlovic B, Bokonjic D, Ignjatovic L, **Mikov M**. The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. Eur J Drug Metab Pharmacokinet. 2014; 39(4):243-53. | | | | | | | 178/255 | | 23 | | 1.563 |
| 104. | Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, **Mikov M**, Golocorbin-Kon S, et al. [Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol](https://www.dovepress.com/microencapsulation-as-a-novel-delivery-method-for-the-potential-antidi-peer-reviewed-fulltext-article-DDDT). Drug Des Devel Ther. 2014;8:1221-30. | | | | | | | 17/59 | | 21 | | 3.028 |
| 105. | Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, **Mikov M**, Golocorbin-Kon S, et al. [Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characerization study](https://www.dovepress.com/novel-artificial-cell-microencapsulation-of-a-complex-gliclazide-deoxy-peer-reviewed-fulltext-article-DDDT). Drug Des Devel Ther. 2014;8:1003-12. | | | | | | | 17/59 | | 21 | | 3.028 |
| 106. | Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, **Mikov M**, Lalic-Popovic M, Stojancevic M, Golocorbin-Kon S, Al-Salami H. [Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics](https://link.springer.com/content/pdf/10.1007%2Fs12247-014-9182-5.pdf). J Pharm Innov. 2014;9(2):150-7. | | | | | | | 218/255 | | 23 | | 1.000 |
| 107. | Raskovic A, Cvejic J, Stilinovic N, Golocorbin-Kon S, Vukmirovic S, Mimica-Dukic N, **Mikov M**. [Interaction between different extracts of hypericum perforatum L. From Serbia and pentobarbital, diazepam and paracetamol](http://www.mdpi.com/1420-3049/19/4/3869). Molecules. 2014;19:3869-82. | | | | | | | 22/58 | | 22 | | 2.416 |
| 108. | Vasović V, Vukmirović S, **Mikov M**, Mikov I, Budakov Z, Stilinović N, Milijašević B. [Influence of bile acid derivates on morphine analgesic effect in mice](http://www.doiserbia.nb.rs/img/doi/0042-8450/2014/0042-84501400007V.pdf). Vojnosanit Pregl. 2014;71(8):767-71. | | | | | | | 141/153 | | 23 | | 0.292 |
| 109. | Vasović V, Rašković A, **Mikov M**, Mikov I, Milijašević B, Vukmirović S, Budakov Z. [Effect of aqueous solution of stevioside on pharmacological properties of some cardioactive drugs](http://www.doiserbia.nb.rs/img/doi/0042-8450/2014/0042-84501400014V.pdf). Vojnosanit Pregl. 2014;71(7):667-72. | | | | | | | 141/153 | | 23 | | 0.292 |
| 110. | Raskovic A, Milanovic I, Pavlovic N, Cebovic T, Vukmirovic S, **Mikov M**. [Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential](https://bmccomplementalternmed.biomedcentral.com/track/pdf/10.1186/1472-6882-14-225?site=bmccomplementalternmed.biomedcentral.com). BMC Complem Altern M 2014; 14: 225. (9 p.). | | | | | | | 6/24 | | 21 | | 2.020 |
| 111. | Stojančević M, Bojić G, Salami HA, **Mikov M**. [The influence of intestinal tract](http://www.caister.com/cimb/v/v16/55.pdf)  [and probiotics on the fate of orally administered drugs](http://www.caister.com/cimb/v/v16/55.pdf). Curr Issues Mol Biol.  2014;16:55-68. | | | | | | | 7/79 | | 21a | | 5.750 |
| 112. | Stojančević M, Pavlović N, Goločorbin-Kon S, **Mikov M**. Application [of bile acids in drug formulation and delivery](http://www.tandfonline.com/doi/full/10.1080/21553769.2013.879925?scroll=top&needAccess=true). HFSP J. 2013;7(3-4):112-22. | | | | | | | 48/55 | | 23 | | 0.227 |
| 113. | **Lalic-Popovic М**, **Paunkovic Ј**, **Grujic Z**, **Golocorbin-Kon S**, **Al-Salami H, Mikov M**. [Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women](https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/1471-2393-13-188). BMC Pregnancy Childbirth. 2013;1**3(**188). doi:10.1186/1471-2393-13-188 | | | | | | | 39/199  (2012) | | 21  (2012) | | 2.516  (2012) |
| 114. | Stepanov V, Stankov K, **Mikov M**. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct. 2013; 33(4):213-23. | | | | | | | 237/291 | | 23 | | 1.611 |
| 115. | Lalić-Popović M, Vasović V, Milijašević B, Goločorbin-Kon S, Al-Salami H, **Mikov M**. [Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat](https://www.hindawi.com/journals/jdr/2013/598603/). J Diabetes Res. 2013;2013:1-8.  *Napomena*: prethodni naslov časopisa Experimental Diabetes Research | | | | | | | 123/124 | | 23 | | 0.000 |
| 116. | Stankov K, Sabo A, **Mikov M**. [Pharmacogenetic Biomarkers as tools for pharmacoepidemiology of severe adverse drug reactions](http://onlinelibrary.wiley.com/doi/10.1002/ddr.21050/pdf). Drug Dev Res. 2013;74:1-14. | | | | | | | 219/256 | | 23 | | 0.734 |
| 117. | Stanimirov B, Stankov K, **Mikov M**. Pleiotropic functions of bile acids mediated by farnesoid X receptor. Acta Gastroenterol Belg. 2012;75(4):389-98. | | | | | | | 68/74 | | 23 | | 0.581 |
| 118. | Mikov I, Stankov K, Vasovic V, Mikov A, Golocorbin – Kon S, **Mikov M**. [Effects of simultaneous exposure to benzene and ethanol on urinary thioesters excretion](http://archiwum.ciop.pl/50499). Int J Occup Saf Ergon. 2012;18(1):107-11. | | | | | | | 218/239 | | 23 | | 0.494 |
| 119. | Stankov K, Draskovic D, **Mikov M**. Ethical and legal aspects of oncogenomics. J BUON. 2012;17(2):383-8. | | | | | | | 184/197 | | 23 | | 0.761 |
| 120. | Stojančevic M, Stankov K, **Mikov M**. [The impact of FXR activation on intestinal permeability in inflammatory bowel disease](https://www.hindawi.com/journals/cjgh/2012/538452/abs/). Can J Gastroenterol. 2012;26(9):631-7. | | | | | | | 58/74 | | 23 | | 1.532 |
| 121. | Pavlović N, Stankov K, **Mikov M**. [Probiotics - interactions with bile acids and impact on cholesterol metabolism](http://download.springer.com/static/pdf/153/art%253A10.1007%252Fs12010-012-9904-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12010-012-9904-4&token2=exp=1491820321~acl=%2Fstatic%2Fpdf%2F153%2Fart%25253A10.1007%25252Fs12010-012-9904). Appl Biochem Biotechnol. 2012;168(7):1880-95. | | | | | | | 87/160 | | 22 | | 1.893 |
| 122. | Velickovic-Radovanovic R, **Mikov M**, Catic-Djordjevic A, Stefanovic N, Stojanovic M, Jokanovic M, Cvetkovic T. [Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: sex differences](http://ac.els-cdn.com/S1550857912001854/1-s2.0-S1550857912001854-main.pdf?_tid=c6c5ad24-6b89-11e7-b1d3-00000aab0f02&acdnat=1500362695_251750cc2ec0e0183ccb2ff56a4a5e04). Gend Med. 2012 Dec;9(6):471-80. | | | | | | | 37/155  (2011) | | 21  (2011) | | 2.101  (2011) |
| 123. | Pavlović N, Stanimirov B, Stojančević M, Paut- Kusturica M, Stoimenova A, Goločorbin-Kon S, **Mikov M**. [An Insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden](http://www.tandfonline.com/doi/pdf/10.5504/BBEQ.2012.0085?needAccess=true). Biotechnol Biotec Eq. 2012;26(5):3236-41. | | | | | | | 137/160 | | 23 | | 0.622 |
| 124. | Al-Salami H, Butt G, Tucker I, Goločorbin-Kon S, **Mikov M**. [Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats](https://link.springer.com/content/pdf/10.1007%2Fs13318-011-0060-y.pdf). Eur J Drug Metab Ph. 2012;37(2):99-108. | | | | | | | 213/261 | | 23 | | 0.944 |
| **Збирни подаци научне активност наставника** | | | | | | | | | | | | |
| Укупан број цитата, без аутоцитата | | | | 2559 | | | | | | | | |
| Укупан број радова са SCI (или SSCI) листе | | | | 171 | | | | | | | | |
| Тренутно учешће на пројектима | | | | Домаћи: 1 | | Међународни: 1 | | | | | | |
| Усавршавања | | | | 1987-1989 Империал Колеџ Лондон; 2004-2008 Фармацеутски факултет Нови Зеланд | | | | | | | | |
| Други подаци које сматрате релевантним | | | | Универзитетски уџбеник: Самојлик И, Миков М. (уредници): Фармакологија са токсикологијом, Уџбеник за студенте стоматологије, Медицијнски факултет Нови Сад, ИСБН 978-86-7197-478-3; Универзитетски уџбеник: Васовић В., Ђаковић К., Миков М., (ед) Одабрана поглавља из токсикологије, Кула, пп 74-83,2009ИСБН 9788684921-05-7 Одобрено од стране Наставно научног већа Медицинског факултета Универзитета у Новом Саду као уџбеник за додипломску наставу; Приручник: Голочорбин-Кон С., Миков М. Одабрана поглавља из клиничке фармације, Ортомедикс, Нови Сад, стр.1-55.2010 ИСБН 978-86-86767-25-7; Књига: Миков М, Бојић Милићевић Г, Сувајџић Љ, Голочорбин-Кон С, Пробиотици, Пребиотици и терапија лековима, Ортомедикс, Нови Сад, цд, стр. 64, 2006 ИСБН 86-7120-049-3. ; Mikov M, Fawcett JP (editors) (2007): Bile acids: Chemistry, biosynthesis, analysis, chemical and metabolic transformations. Mediset Publisher, Geneva, 226 pages, ISBN 0-12-045783-2; Књига:Миков М, Бојић Милићевић Г, Сувајџић Љ, Голочорбин-Кон С, Пробиотици, Пребиотици,синбиотици: Нове могућности терапијске примене, Ортомедикс, Нови Сад, цд, стр. 64, 2005 ИСБН86-7120-043-4 Одобрено од стране Наставно научног већа Медицинског факултета Универзитета у Новом Саду као помоћни уџбеник за последипломску наставу; Поглавље у књизи: Томић З, Миков М, Сабо А, Јаковљевић В, Голочорбин-Кон С. Регистар лјекова Црне Горе 2002(Томић З ед.) Фонд за здравство Црне Горе., Подгорица.; Поглавље у књизи од међународног значаја; Al-Salami H, Caccetta R, Goločorbin-Kon S, Mikov M. Probiotics Applications. In: Rigobelo EC, editor. Autoimmune Diseases. New York: In Tech; 2012.p. 325-366 ISBN 978-953-51-1776-7: Knjiga medjunarodnog znacaja:Mikov M, Fawcett JP (editors) (2007): Bile acids: Chemistry, biosynthesis, analysis, chemical and metabolic transformations. Mediset Publisher, Geneva, 226 pages, ISBN 0-12-045783-2.; Поглавље у књизи од међународног значаја: Mikov M, AlSalami H, Golocorbin-Kon S, “Potentials and limitations of bile Acids and probiotics inDiabetes Mellitus, type 1 Diabetes-Complications, Pathogenesis, and alternative Treatments, Chih-Pin Liu(Ed.), In Tech, 2011 ISBN 978-953-307-756-7. ; Монографије, посебна поглавља у научним књигама (Mikov M, Skrbic R, Fawcett P (editors) Sulphasalazine past, present and future challenges. Medical faculty, University of Banja Luka pp.43-47, 2009 ISBN 978-99938-42-40-8. | | | | | | | | |